Luxembourg, Luxembourg
Luxembourg, Luxembourg

Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental and consumer products industries and to governments. Eurofins employs more than 15,000 employees across around 190 sites in 36 countries and has about EUR 1.1 billion annual revenues .The Eurofins Group offers a portfolio of over 100,000 reliable analytical methods for characterising the safety, identity, purity, composition, authenticity and origin of products and biological substances. Through research and development, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical science.Eurofins pursued an aggressive strategy of expansion, buying more than eighty competitors worldwide since it was founded. Notable examples include the acquisition in 2005 of the German company MWG-Biotech and in 2011 of the US company Lancaster Laboratories, the latter for 150  million euros. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

North America is estimated to hold a whopping 45.3% value share in the global GMP cell banking services market by the end of 2017 and will witness an increase of 231 basis points in market share by 2025 over 2017. The North America regional market will create absolute $ opportunity of US$ 23 Mn in 2018 over 2017. In a new report titled "Global Market Study on GMP Cell Banking Services: Mammalian Cell Type Segment Revenue Projected to Grow 3.2x by 2025 End as Compared to that in 2017," Persistence Market Research forecasts revenue from the North America market to grow 3.1x by 2025 end as compared to that in 2017. This will directly impact the global GMP cell banking services market, which will likely grow from US$ 346.6 Mn in 2017 to US$ 1,012.4 Mn by the end of 2025, translating into a CAGR of 14.3% during the eight year forecast period 2017 - 2025. Strategic industry consolidations and increase in demand for Ready-to-Use (RTU) Bioassay Banks is trending the global GMP cell banking services market One of the key objectives of the report is to identify the key trends governing the global GMP cell banking services market and present a clear picture of the various forces impacting the market at a micro and macro level. A sustained growth of the market can be attributed to macro-economic drivers such as increased public and private sector funding for disease research, which is expected to bring newer therapies to the market; high costs of clinical development; and various collaborative initiatives to identify therapies for difficult-to-treat illnesses. On the supply side, an expansion of production facilities by key players to meet growing customer demand besides offering customized solutions based on specific customer needs (this involves strategic tie-ups between biopharmaceutical companies and cell banking service providers) are some of the factors likely to push the global GMP cell banking services market ahead in the coming years. The report also identifies certain demand side drivers boosting the market such as a growing number of biologics in development currently, limited in-house storage and testing capabilities and a rise in the demand for outsourcing and contract manufacturing. While the above growth factors are indicative of a mature market, Persistence Market Research identifies certain pull factors likely to restrain the market to a certain extent in the coming years. First off, the global GMP cell banking services market is highly fragmented with multiple vendors offering a variety of services - resulting in limited global reach. Besides, complexities in the production and manufacturing processes, a constantly evolving technology landscape, and inconsistent demand for services are likely to restrain revenue growth of the global GMP cell banking services market during the forecast period. Persistence Market Research predicts a large opportunity for key players in the fast growing Asia Pacific region. It must be noted that there has been a shift of R&D and technology investments in the healthcare industry from North America and Europe to Asia Pacific with developing APAC economies such as India offering increased scope for outsourcing of biotech projects owing to ample skilled and qualified manpower at optimal costs. A sample of this report is available upon request@ http://www.persistencemarketresearch.com/samples/13735 Mammalian cell type segment to retain its pole position throughout the forecast period Among the cell type segments, the Mammalian segment was the dominant segment in 2016 and is expected to retain its dominance through 2025. From an estimated US$ 216 Mn in 2017 to a market valuation in excess of US$ 680 Mn by the end of the forecast period, the Mammalian segment will register the highest CAGR of 15.6% among the other cell type segments. The Microbial segment is the second most attractive cell type segment in the global GMP cell banking services market in terms of revenue. Registering a value CAGR of 12.9% between 2017 and 2025, the Microbial segment will hold the second position among the cell type segments of the global GMP cell banking services market. Biopharmaceutical Companies will be the largest end users of GMP cell banking services Among the end user segment of the global GMP cell banking services market, the Biopharmaceutical Companies segment will emerge the undisputed leader both in terms of market share (estimated to hold almost 69% share by 2017 end) and CAGR (an impressive 15.4% during 2017 - 2025). In comparison, the Contract Manufacturing Organizations segment will come a pale second, recording a market attractiveness index of 0.5 during the forecast period. Request to View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/gmp-cell-banking-service-market/toc The top companies profiled in the report include Wuxi AppTec, Charles River Laboratories International Inc, Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices Inc. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces that it has acquired four clinical laboratories in France since the beginning of 2017, as part of the Group’s strategy to strengthen its footprint in clinical diagnostics to better serve the healthcare industry in the country. The Group acquired iLab in Provence-Alpes-Côte d'Azur and Biosphere in Rhône-Alpes, consolidating the Group’s footprint in these regions. In addition, the Group has also acquired two groups of laboratories in Marseille and Martigues, both focused on specialty clinical testing. The 4 laboratories have combined annual revenues in excess of EUR 10m. The acquisitions are consistent with Eurofins’ strategy to strengthen its market position in the core regions of France, and to further develop as a national player with strong local footprint. Comment from Dr. Gilles Martin, Eurofins CEO: “ These transactions demonstrate Eurofins’ commitment to developing its clinical diagnostics platform, which should enable the Group to continue deploying its technical know-how and proprietary technologies, including its competencies in specialty diagnostic testing, in France and throughout the rest of Europe.” For more information, please visit www.eurofins.com Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 28,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP). This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.91M | Year: 2015

Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are frequent, chronic and highly heritable neurodevelopmental disorders. Despite their societal importance, progress in understanding disease biology has been slow and no curative treatment options are available. The pan-European training network MiND aims to educate a new generation of researchers in the field of neurodevelopmental disorders, through innovation-oriented research combined with highly interdisciplinary and intersectoral international training. Research and training in MiND span state-of-the-art topics in the fields of ADHD, ASD and their yet un-investigated overlap. We combine advanced (epi-)genetics approaches with bioinformatics and develop novel cell and animal models of increasing complexity to understand pathomechanisms. Integrated with research in large human DNA-neuroimaging-cognition data sets, we push forward the understanding of the biology leading from gene to cognition and disease. Our mechanistic work is embedded in a framework exploring alternative disease definitions for ADHD and ASD across the lifespan and working towards improved treatment: we use novel cognitive assessments, we probe the microbiome for dietary interventions reducing symptoms and evaluate mindfulness training as non-pharmacological treatment options, in addition to developing new compounds for pharmacological treatment optimization and individualization. The strategic collaboration of world-leading academic groups, research-intensive commercial enterprises and patient organisations will deliver 15 young, scientifically excellent researchers which are optimally prepared for private sector and academic careers. MiND can be expected to impact patients and society by improving our understanding of disease biology, by developing novel diagnostic and treatment strategies, and by raising awareness for the necessity of research of neurodevelopmental disorders from childhood to adulthood.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.3.5-01 | Award Amount: 3.85M | Year: 2013

The Decathlon project will bring together a broad range of experts and expertise to jointly work on the development of new or improved methods that are needed in the field of 1) food pathogens, 2) traceability of GMOs and 3) customs issues. The project will develop advanced methods for all three application areas with method characteristics that meet the requirements of the individual areas, as will be laid down in minimal performance parameters (MPPs) for the types of methods as will be developed within the Decathlon project. Decathlon brings together all relevant molecular biological and bioinformatics expertise through the participation of expert European researchers in the respective fields of application. Besides technical experts, also field-related, application-oriented scientists will participate for the three areas of interest, which are fully aware of the user requirements for the methods to be developed, also in the light of current and future European regulations. By combining this awareness with technical expertise, user requirements will be translated into technical and bioinformatics method requirements that will form the starting-point for the molecular biological technical methods (including any related bioinformatics module, where applicable) to be developed. In this way the Decathlon project will develop focused DNA-based (on-site) methods for the identified areas of food pathogens, GMOs and customs issues, and at the same time stimulate the development of DNA methods for similar applications in numerous other fields that require high-quality, focused DNA-based detection and identification methods. Decathlon will provide the roadmap and blueprint for this broader application of all methods and modules developed in Decathlon. Furthermore, Decathlon will have the cooperation platform and network in place that will be extended effectively throughout the duration of the project as a consolidated European network of analytical experts.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.3-1 | Award Amount: 12.95M | Year: 2013

The NanoMILE project is conceived and led by an international elite of scientists from the EU and US with the aim to establish a fundamental understanding of the mechanisms of nanomaterial interactions with living systems and the environment, and uniquely to do so across the entire life cycle of nanomaterials and in a wide range of target species. Identification of critical properties (physico-chemical descriptors) that confer the ability to induce harm in biological systems is key to allowing these features to be avoided in nanomaterial production (safety by design). Major shortfalls in the risk analysis process for nanomaterials are the fundamental lack of data on exposure levels and the environmental fate and transformation of nanomaterials, key issues that this proposal will address, including through the development of novel modelling approaches. A major deliverable of the project will be a framework for classification of nanomaterials according to their impacts, whether biological or environmental, by linking nanomaterial-biomolecule interactions across scales (sub-cellular to ecosystem) and establishing the specific biochemical mechanisms of interference (toxicity pathway).


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.4-3 | Award Amount: 9.29M | Year: 2013

Nanotechnology is a key enabling technology. Still existing uncertainties concerning EHS need to be addressed to explore the full potential of this new technology. One challenge consists in the development of methods that reliably identify, characterize and quantify nanomaterials (NM) both as substance and in various products and matrices. The European Commission has recently recommended a definition of NM as reference to determine whether an unknown material can be considered as nanomaterial (2011/696/EU). The proposed NanoDefine project will explicitly address this question. A consortium of European top RTD performers, metrology institutes and nanomaterials and instrument manufacturers has been established to mobilize the critical mass of expertise required to support the implementation of the definition. Based on a comprehensive evaluation of existing methodologies and a rigorous intra-lab and inter-lab comparison, validated measurement methods and instruments will be developed that are robust, readily implementable, cost-effective and capable to reliably measure the size of particles in the range of 1100 nm, with different shapes, coatings and for the widest possible range of materials, in various complex media and products. Case studies will assess their applicability for various sectors, including food/feed, cosmetics etc. One major outcome of the project will be the establishment of an integrated tiered approach including validated rapid screening methods (tier 1) and validated in depth methods (tier 2), with a user manual to guide end-users, such as manufacturers, regulatory bodies and contract laboratories, to implement the developed methodology. NanoDefine will be strongly linked to main standardization bodies, such as CEN, ISO and OECD, by actively participating in TCs and WGs, and by proposing specific ISO/CEN work items, to integrate the developed and validated methodology into the current standardization work.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2013.2.4-01 | Award Amount: 11.53M | Year: 2014

Food Integrity the state of being whole, entire, or undiminished or in perfect condition. Providing assurance to consumers and other stakeholders about the safety, authenticity and quality of European food (integrity) is of prime importance in adding value to the European Agri-food economy. The integrity of European foods is under constant threat from fraudulently labelled imitations that try to exploit that added value. The FOODINTEGRITY project will directly address this issue and will be an international focal point for harmonisation and exploitation of research and technology for insuring the integrity of European food. Comprising an inner core of project participants from industry, academia, research institutes, technology providers and a global network of stakeholders, FOODINTEGRITY will rationalise and harmonise capability to provide a coherent structure and process for assuring the food supply. FOODINTEGRITY will: facilitate the sharing of information between stakeholder groups regarding European food integrity; establish processes for harmonising & exploiting existing databases; establish fit for purpose methodology to address stakeholder needs; identify and address research gaps by procuring and delivering 3M of commissioned projects; establish a self-sustaining Food-fraud early warning system for identifying emerging fraud risks; establish a self-sustaining worldwide network of stakeholders to ensure maximum uptake of the project legacy. Improved verification procedures will be developed for food control and industry stakeholders using 3 key commodities as exemplars: olive oil, spirit drinks & seafood. In addition a consumer study in China will assess their consumer attitudes in the face of substantial counterfeiting of European food. Finally it will establish expert food authenticity platforms that will supply independent expert opinion on food authenticity/food fraud to the European Commission, Codex and other national/international bodies


Grant
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.2.4-04 | Award Amount: 12.16M | Year: 2013

Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners) and allergens (by industry) is thwarted by lack of evidence to either prevent food allergy developing or protect adequately those who are already allergic. iFAAM will develop evidence-based approaches and tools for MANAGEMENT of ALLERGENS in FOOD and integrate knowledge derived from their application and new knowledge from intervention studies into FOOD ALLERGY MANAGEMENT plans and dietary advice. The resulting holistic strategies will reduce the burden of food allergies in Europe and beyond, whilst enabling the European food industry to compete in the global market place. Our approach will build on e-Health concepts to allow full exploitation of complex data obtained from the work in this proposal and previous and ongoing studies, maximising sharing and linkage of data, by developing an informatics platform Allerg-e-lab. This will enable us to (1) Extend and integrate existing cohorts from observation and intervention studies to provide evidence as to how maternal diet and infant feeding practices (including weaning) modulate the patterns and prevalence of allergies across Europe (2) Establish risk factors for the development of severe reactions to food and identify associated biomarkers (3) Develop a clinically-validated tiered risk assessment and evidence-based risk management approach for food allergens for allergens in the food chain (4) Develop clinically-relevant multi-analyte methods of analysis suited to allergen management across the food chain Stakeholders will be integrated into iFAAM to deliver harmonised integrated approaches, including RISK ASSESSORS AND MANAGERS managing population risk, the FOOD INDUSTRY who manage allergens to ensure consumer safety, HEALTH CARE PRACTITIONERS to provide food allergy management plans and dietary advice and ALLERGIC CONSUMERS to manage individual risk.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2011.3.2 | Award Amount: 4.00M | Year: 2012

Concern for our food is growing in Europe, driven by industrialised food production and repeated crises. Current analytical technology is too expensive and bound to the laboratory to test more than a small fraction of 1% of the EUs food. This problem requires more massive screening of food and water extending from the source to the point of consumption. A low-cost and portable system delivering analytical data to a central location would help to prevent or identify early any food safety threat outbreaks and thereby massively reduce human suffering and its associated financial cost on both sides of the global divide. FOODSNIFFER is field-deployable and simple-to-use as a result of the integration of three major innovations: (i) the transducer itself, an all-silicon fully integrated optoelectronic platform based on Broad-Band Mach-Zehnder Interferometry capable of synchronous highly-sensitive label-free multi-analyte detection. This ultimately-integrated transducer due to the incorporation of the light-sources, sensing elements, spectral analyzer and photodetectors, in a single chip, can be used in single-shot cartridges. (ii) the innovative design of the wafer-scale microfluidics and filtration systems that unburden the reader of external pumps/valves, and intensive sample preparation. (iii) the development of a low-power reader controlled by a smartphone through a custom-produced application. The software controls the sensor and also processes its signal and then sends the results securely via the internet during the on-the-spot food safety analysis. FOODSNIFFER is a complete business solution which will be demonstrated in three areas of great importance to European society and regulators, viz. the detection of pesticide residues, mycotoxins and allergens in selected food categories in order to demonstrate field-based detection of harmful species at low concentrations, which is a feat unattained so far by any point-of-need system.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SFS-14a-2014 | Award Amount: 5.35M | Year: 2016

The OLEUM project will generate innovative, more effective and harmonized analytical solutions to detect and fight the most common and emerging frauds and to verify the overall quality of olive oils (OOs). By a core group of 20 partners from 15 countries OLEUM will undertake RESEARCH ACTIVITIES based on the development of IMPROVED and NEW ANALYTICAL METHODS by targeted and omics approaches with the aim: i) to detect new markers of the soft deodorization process; ii) to discover illegal blends between OOs and other vegetable oils; iii) to control OO quality (e.g. freshness); iv) to improve the organoleptic assessment with a Quantitative Panel Test, based on current official methods, and supported by tailored reference materials for better calibration of the sensory panels coupled with rapid screening tools to facilitate the work of the panelists. The most promising OLEUM solutions will be subjected to VALIDATION in conformity with internationally agreed standards by peer laboratories. OLEUM will recreate a realistic deodorization scenario by producing tailored, soft deodorized OOs by lab-scale and up-scaled pilot plants to apply analytical solutions to known samples. Substantial KNOWLEDGE and TECHNOLOGY TRANSFER activities will be envisaged to aid in implementation of: a) a web-based easily-accessible, scalable and constantly updated OLEUM DATABANK, containing all the information from OLEUM research and other reliable international sources, will be available for download data and spectra and to help achieve satisfactory harmonization of analytical approaches among control laboratories; b) the OLEUM NETWORK of relevant OOs stakeholders to maximize the impact of proposed analytical solutions. Finally, a robust dissemination strategy by the OLEUM project aimed at effectively sharing results with all stakeholders in the OO supply chain has the potential to improve consumer and market confidence, and preserve the image of OOs on a global scale.

Loading Eurofins collaborators
Loading Eurofins collaborators